ImmunityBio (IBRX) Interest Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Interest Expenses data on file, last reported at $77.1 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 394.28% year-over-year to $77.1 million in Q1 2026; TTM through Mar 2026 was $77.1 million, a 23.48% decrease from a year earlier, with the FY2025 full-year figure at $855.8 million, up 10.13% from the prior year.
• Interest Expenses for Q1 2026 stood at $77.1 million, up from $14.8 million in the prior quarter.
• Over the last five years, Interest Expenses for IBRX reached as high as $77.1 million in Q1 2026 and fell as low as -$18.7 million in Q4 2022.
• Historically, Interest Expenses has averaged $21.6 million across 5 years, with a median of $16.8 million in 2022.
• Across the five-year window, Interest Expenses sank 3014.53% in 2022 and jumped 6405.25% in 2024, its largest moves.
• Year by year, Interest Expenses stood at -$18.7 million in 2022, then surged by 102.14% to $400000.0 in 2023, then soared by 6405.25% to $26.0 million in 2024, then slumped by 42.96% to $14.8 million in 2025, then surged by 419.25% to $77.1 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $77.1 million in Q1 2026, $14.8 million in Q4 2025, and $15.3 million in Q3 2025.